Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture - PubMed (original) (raw)

Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture

I Bahner et al. J Virol. 1996 Jul.

Abstract

Genetic modification of hematopoietic stem cells with a synthetic "anti-human immunodeficiency virus type 1 (HIV-1) gene" which inhibits replication of HIV-1 may allow production of mature lymphoid and monocytic cells resistant to HIV-1 growth after autologous transplantation. Because productive HIV-1 replication requires binding of the Rev protein to the Rev-responsive element (RRE) within the viral transcripts for the HIV-1 structural proteins, anti-HIV-1 gene products which interfere with Rev-RRE interactions may inhibit HIV-1 replication. One such strategy involves overexpression of the RRE sequences in transcripts derived from retroviral vectors to act as decoys to sequester Rev protein and prevent its binding to the RRE element in HIV-1 transcripts. We developed an in vitro model to test the efficacy of this gene therapy approach in primary human hematopoietic cells. Human CD34+ hematopoietic progenitor cells from normal bone marrow or umbilical cord blood were transduced with retroviral vectors carrying RRE decoy sequences as part of a long terminal repeat-directed transcript expressing the neo gene (L-RRE-neo) or with a control vector expressing only the neo gene (LN). The transduced progenitors were allowed to differentiate into mature myelomonocytic cells which were able to support vigorous growth of the monocytotropic isolate of HIV-1, JR-FL. HIV-1 replication was measured in unselected cell populations and following G418 selection to obtain uniformly transduced cell populations. Inhibition of HIV-1 replication in the unselected cell cultures was between 50.2 and 76.7% and was highly effective (99.4 to 99.9%) in the G418-selected cultures. Progenitors transduced by either the L-RRE-neo vector or the control LN vector were identical with respect to hematopoietic growth and differentiation. These findings demonstrate the ability of an RRE decoy strategy to inhibit HIV-1 replication in primary human myelomonocytic cells after transduction of CD34+ progenitor cells, without adverse effects on hematopoietic cell function.

PubMed Disclaimer

Similar articles

• Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
  Lee SW, Gallardo HF, Gilboa E, Smith C. Lee SW, et al. J Virol. 1994 Dec;68(12):8254-64. doi: 10.1128/JVI.68.12.8254-8264.1994. J Virol. 1994. PMID: 7966618 Free PMC article.
• Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys.
  Smith C, Lee SW, Wong E, Gallardo H, Page K, Gaspar O, Lebkowski J, Gilboa E. Smith C, et al. Antiviral Res. 1996 Oct;32(2):99-115. doi: 10.1016/0166-3542(95)00987-6. Antiviral Res. 1996. PMID: 8891169
• Inhibition of HIV-1 replication by targeting the Rev protein.
  Nakaya T, Iwai S, Fujinaga K, Otsuka E, Ikuta K. Nakaya T, et al. Leukemia. 1997 Apr;11 Suppl 3:134-7. Leukemia. 1997. PMID: 9209321 Review.
• Structural Fluidity of the Human Immunodeficiency Virus Rev Response Element.
  Sherpa C, Grice SFJL. Sherpa C, et al. Viruses. 2020 Jan 11;12(1):86. doi: 10.3390/v12010086. Viruses. 2020. PMID: 31940828 Free PMC article. Review.

Cited by

• HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector.
  Anderson J, Akkina R. Anderson J, et al. AIDS Res Ther. 2005 Jan 13;2(1):1. doi: 10.1186/1742-6405-2-1. AIDS Res Ther. 2005. PMID: 15813990 Free PMC article.
• Nucleic acids-based therapeutics in the battle against pathogenic viruses.
  Haasnoot J, Berkhout B. Haasnoot J, et al. Handb Exp Pharmacol. 2009;189(189):243-63. doi: 10.1007/978-3-540-79086-0_9. Handb Exp Pharmacol. 2009. PMID: 19048203 Free PMC article. Review.
• CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.
  Anderson J, Akkina R. Anderson J, et al. Retrovirology. 2005 Aug 18;2:53. doi: 10.1186/1742-4690-2-53. Retrovirology. 2005. PMID: 16109172 Free PMC article.
• The foamy virus genome remains unintegrated in the nuclei of G1/S phase-arrested cells, and integrase is critical for preintegration complex transport into the nucleus.
  Lo YT, Tian T, Nadeau PE, Park J, Mergia A. Lo YT, et al. J Virol. 2010 Mar;84(6):2832-42. doi: 10.1128/JVI.02435-09. Epub 2009 Dec 23. J Virol. 2010. PMID: 20032182 Free PMC article.
• The use of cell-delivered gene therapy for the treatment of HIV/AIDS.
  Symonds GP, Johnstone HA, Millington ML, Boyd MP, Burke BP, Breton LR. Symonds GP, et al. Immunol Res. 2010 Dec;48(1-3):84-98. doi: 10.1007/s12026-010-8169-7. Immunol Res. 2010. PMID: 20737298 Review.

References

1. 1. Blood. 1992 Mar 15;79(6):1393-9 - PubMed
2. 1. Biol Blood Marrow Transplant. 1995 Nov;1(1):3-17 - PubMed
3. 1. J Exp Med. 1992 Oct 1;176(4):1197-201 - PubMed
4. 1. Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9870-4 - PubMed
5. 1. Somat Cell Mol Genet. 1986 Mar;12(2):175-83 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database